Stock Research for BLRX

BLRX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

BLRX Stock Chart & Research Data

The BLRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BLRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


BLRX Due diligence Resources & Stock Charts

The BLRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BLRX Detailed Price Forecast - CNN Money CNN View BLRX Detailed Summary - Google Finance
Yahoo View BLRX Detailed Summary - Yahoo! Finance Zacks View BLRX Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View BLRX Trends & Analysis - Trade-Ideas Barrons View BLRX Major Holders - Barrons
NASDAQ View BLRX Call Transcripts - NASDAQ Seeking View BLRX Breaking News & Analysis - Seeking Alpha
Spotlight View BLRX Annual Report - CompanySpotlight.com OTC Report View BLRX OTC Short Report - OTCShortReport.com
TradeKing View BLRX Fundamentals - TradeKing Charts View BLRX SEC Filings - Bar Chart
WSJ View Historical Prices for BLRX - The WSJ Morningstar View Performance/Total Return for BLRX - Morningstar
MarketWatch View the Analyst Estimates for BLRX - MarketWatch CNBC View the Earnings History for BLRX - CNBC
StockMarketWatch View the BLRX Earnings - StockMarketWatch MacroAxis View BLRX Buy or Sell Recommendations - MacroAxis
Bullish View the BLRX Bullish Patterns - American Bulls Short Pains View BLRX Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View BLRX Stock Mentions - StockTwits PennyStocks View BLRX Stock Mentions - PennyStockTweets
Twitter View BLRX Stock Mentions - Twitter Invest Hub View BLRX Investment Forum News - Investor Hub
Yahoo View BLRX Stock Mentions - Yahoo! Message Board Seeking Alpha View BLRX Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for BLRX - SECform4.com Insider Cow View Insider Transactions for BLRX - Insider Cow
CNBC View BLRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BLRX - OTC Markets
Yahoo View Insider Transactions for BLRX - Yahoo! Finance NASDAQ View Institutional Holdings for BLRX - NASDAQ


Stock Charts

FinViz View BLRX Stock Insight & Charts - FinViz.com StockCharts View BLRX Investment Charts - StockCharts.com
BarChart View BLRX Stock Overview & Charts - BarChart Trading View View BLRX User Generated Charts - Trading View




Latest Financial News for BLRX


BioLineRx Announces Initiation of Triple Combination Arm of Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer Under Immuno-Oncology Collaboration
Posted on Tuesday December 11, 2018

TEL AVIV, Israel, Dec. 11, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the initiation of the triple combination arm of the Phase 2a COMBAT/KEYNOTE-202 study in patients with metastatic pancreatic cancer (PDAC) under its immuno-oncology collaboration with Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada). As previously announced, the triple combination arm will investigate the safety, tolerability and efficacy of BL-8040, KEYTRUDA and chemotherapy.


BioLineRx to Host Investor and Analyst Breakfast Meeting on December 11, 2018 in New York
Posted on Thursday December 06, 2018

BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will host an investor breakfast meeting on Tuesday, December 11, 2018 at the Convene Conference Center near Grand Central Terminal in New York, N.Y. BL-8040 is a short peptide that functions as a high-affinity antagonist for CXCR4 in late clinical development for the treatment of solid tumors, acute myeloid leukemia (AML) and stem-cell mobilization for bone-marrow transplantation.


New Healthcare Trends Have Investors Looking at 4 Stocks
Posted on Tuesday November 20, 2018

Heading into the holiday week, a number of healthcare names are taking hold of a bull market in healthcare stocks. HealthVue currently has an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally.


BioLineRx Announces Receipt of FDA Biological Product Designation for Novel Cancer Immunotherapy Candidate AGI-134
Posted on Tuesday November 20, 2018

TEL AVIV, Israel, Nov. 20, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that the U.S. Food and Drug Administration (FDA) has granted the Biological Product Designation for AGI-134, the Company's novel immunotherapy compound. This designation provides the Company with eligibility to obtain 12 years of market exclusivity upon approval of the product for commercial use by the FDA.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.